On this episode of The HemOnc Pulse, guest Jonathan Friedberg, MD, MMSc, a hematologic oncologist at the University of Rochester Medicine – Wilmot Cancer Institute, chats with host Dr. Chadi Nabhan on the subtle but important shift in the treatment landscape of diffuse large B-cell lymphoma (DLBCL)in the post-POLARIX trial era.

The POLARIX trial, which was designed to improve upon the standard R-CHOP regimen for DLBCL treatment, investigated the potential of polatuzumab vedotin. The phase III trial ultimately resulted in the US Food and Drug Administration approving the treatment in previously untreated DLBCL, not otherwise specified, or high-grade B-cell lymphoma. The approval is for patients with an International Prognostic Index (IPI) score of two or greater.

"I think that this was a robustly done randomized placebo-controlled trial that showed a small but clinically significant benefit as far as progression-free survival in patients with IPI score of two and above [in] large B cell lymphoma," he said.

The Post-POLARIX Trial Era: Polatuzumab Vedotin Shifts DLBCL Treatment

In this episode of The HemOnc Pulse, Dr. Maddocks, Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University, charts the treatment evolution of mantle cell lymphoma (MCL) from frontline therapy to future directions. She also explains her initial shock, and subsequent bittersweet reaction to the withdrawal of ibrutinib.

Kami Maddocks, MD, on the Shocking Ibrutinib Withdrawal

In this episode of The HemOnc Pulse, Grzegorz Nowakowski MD, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic, recounts his experience serving on the FDA Oncologic Drugs Advisory Committee that reviewed and evaluated data from the POLARIX study and polatuzumab vedotin-piiq (Polivy)for patients with previously untreated LBCL.

Inside the FDA ODAC 'Yes' Vote to Polivy

In this episode of The HemOnc Pulse, Alan Skarbnik, MD, of Novant Health, discusses practice-changing research in diffuse large B-cell lymphoma (DLBCL) presented at the 65th American Society of Hematology Annual Meeting & Exposition.
 
Dr. Skarbnik looks at chimeric antigen receptor T-cell infusion in patients with LBCL in complete remission, a quadruplet therapy in combination with chemotherapy, and more.

What Is the Latest ‘Practice-Changing’ Research in DLBCL?

Dr. Eyre, a consultant hematologist at the Oxford University Hospitals NHS Foundation Trust, talks about blending clinical trials and patient-facing work in the NHS, his research activities, and the top chronic lymphocytic leukemia (CLL) news coming out of the 65th American Society of Hematology Annual Meeting & Exposition.

He also delves into the ongoing debate on the future of Bruton's tyrosine kinase (BTK) inhibitors in CLL.

Toby Eyre, MD, on the Future of BTK Inhibitors in CLL

In this episode of The HemOnc Pulse, Jerald Radich, MD, of the Fred Hutchinson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss various abstracts on acute myeloid leukemia (AML) presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition. The conversation centered around menin inhibitors for the treatment of AML, the effect of measurable residual disease-positivity on transplantation outcomes, and whether age plays a role in transplantation.

Jerald Radich, MD: AML Abstracts to Keep an Eye on at ASH 2023

Saad Usmani, MD, MBA, FACP, Chief of the Myeloma Service at the Memorial Sloan Kettering Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, on The HemOnc Pulse to chat about the latest research in multiple myeloma from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. 

Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing in the hematologic oncology space. He also reflects on the Perseus and IsKia trials, which were presented at ASH 2023.

Dr. Usmani Discusses Perseus, IsKia, Data Plus More Myeloma Updates

Sangeetha Venugopal, MD, of the University of Miami Sylvester Comprehensive Cancer Center, offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes (MDS), the COMMANDS trial, and if she believes MDS is a distinct disease.

She also highlights the latest research in MDS at the 65th American Society of Hematology Annual Meeting and Exposition.

Dr. Venugopal Offers Her Thoughts on the Latest MDS News

The first episode of The HemOnc Pulse of the new year features an in-depth discussion by the leading researchers of the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) consortium.

Principal investigators Susan Parsons, MD, MRP; and Andrew Evans, DO, MBA, MSc; are joined by Matthew Maurer, DMSc; to share the story behind harmonizing the world's Hodgkin lymphoma data, and what the effort means for both clinicians and patients.

What It Takes to Harmonize the World's Hodgkin Lymphoma Data

This episode features a conversation between Dr. Shastri, an Assistant Professor of Medicine at the Montefiore Einstein Comprehensive Cancer Center in the Bronx, New York, and The HemOnc Pulse host, Chadi Nabhan; MD; MBA; FACP; on the latest news in myelodysplastic syndromes (MDS), including the final readout from the COMMANDS trial and the clinical implications of TP53-mutated MDS.

Aditi Shastri, MD: Clinicians Need to ‘Come Together’ on TP53-Mutated MDS

An all-new episode of The HemOnc Pulse with Saurabh Dahiya, MD, FACP, of Stanford Medicine, and Jay Spiegel, MD, of the University of Miami, features a discussion on the link between chimeric antigen receptor (CAR)-T cell therapies and secondary T-cell malignancies. The episode follows on the heels of the US Food and Drug Administration's request to drug manufacturers of the six CAR-T therapies to make safety-related labeling changes.

The Post-POLARIX Trial Era: Polatuzumab Vedotin Shifts DLBCL Treatment

The HemOnc Pulse

Related tracks